Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Fausel

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Managed Care Pharmacy : JMCP|November 27, 2007
Targeted chronic myeloid leukemia therapy: seeking a cureChristopher Fausel
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 11, 2007
Targeted chronic myeloid leukemia therapy: Seeking a cureChristopher Fausel
Pharmacotherapy|January 14, 2003
Recurring chemotherapy-associated alopecia areata: case report and literature reviewSusannah E Motl, Christopher Fausel
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 11, 2007
Leukemia. Q&A highlightsDavid Frame, Jolynn Sessions, Christopher Fausel
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|June 27, 2007
Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugsBrian G Cochran, Kevin M Sowinski, Christopher Fausel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2012
Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group studyCostantine Albany, Mary J Brames, Christopher Fausel, et al.
Frontiers in Oncology|December 6, 2024
A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination defective metastatic esophageal/gastroesophageal junction/proximal gastric adenocarcinomaAhmed Bilal Khalid, Christos Fountzilas, Heather N Burney, et al.
Pharmacotherapy|September 17, 2013
Comparison of an assumption-free Bayesian approach with Optimal Sampling Schedule to a maximum a posteriori Approach for Personalizing Cyclophosphamide DosingJosé M Laínez, Seza Orcun, Joseph F Pekny, et al.
Bone Marrow Transplantation|July 31, 2024
Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myelomaZachary M Avigan, Suzanne Arinsburg, Darren Pan, et al.
Bone Marrow Transplantation|October 18, 2024
Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myelomaZachary M Avigan, Suzanne Arinsburg, Darren Pan, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Managed Care Pharmacy : JMCP|November 27, 2007
Targeted chronic myeloid leukemia therapy: seeking a cureChristopher Fausel
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 11, 2007
Targeted chronic myeloid leukemia therapy: Seeking a cureChristopher Fausel
Pharmacotherapy|January 14, 2003
Recurring chemotherapy-associated alopecia areata: case report and literature reviewSusannah E Motl, Christopher Fausel
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 11, 2007
Leukemia. Q&A highlightsDavid Frame, Jolynn Sessions, Christopher Fausel
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|June 27, 2007
Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugsBrian G Cochran, Kevin M Sowinski, Christopher Fausel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2012
Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group studyCostantine Albany, Mary J Brames, Christopher Fausel, et al.
Frontiers in Oncology|December 6, 2024
A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination defective metastatic esophageal/gastroesophageal junction/proximal gastric adenocarcinomaAhmed Bilal Khalid, Christos Fountzilas, Heather N Burney, et al.
Pharmacotherapy|September 17, 2013
Comparison of an assumption-free Bayesian approach with Optimal Sampling Schedule to a maximum a posteriori Approach for Personalizing Cyclophosphamide DosingJosé M Laínez, Seza Orcun, Joseph F Pekny, et al.
Bone Marrow Transplantation|July 31, 2024
Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myelomaZachary M Avigan, Suzanne Arinsburg, Darren Pan, et al.
Bone Marrow Transplantation|October 18, 2024
Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myelomaZachary M Avigan, Suzanne Arinsburg, Darren Pan, et al.
Pageof 2